Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (12): 713-720.
Previous Articles Next Articles
XI Hao, WANG Chong*
Received:
2019-01-18
Revised:
2019-01-18
Online:
2018-12-20
Published:
2019-01-18
CLC Number:
XI Hao, WANG Chong. Research on Post-marketing Surveillance System of Vaccine in European Union[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 713-720.
[1] Cranfield M R.Vaccination[M]// The International Encyclopedia of Primatology. John Wiley & Sons, Inc. 2017. [2] EMA. EU Administrative Procedure For Official Control Authority Batch Release [EB/OL].(2017-12-28)[2018-09-13].https://www.edqm.eu/sites/default/files/eu-administrative-procedure-ocabr.zip. [3] EMA.Medicines under additional monitoring [EB/OL].(2013-04-25)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Other/2013/04/WC500142430.pdf. [4] WHO. The Importance of Pharmacovigilance: safety monitoring of medicinal products [EB/OL]. (2002-01)[2018-09-13] http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. [5] 刘夏. “反应停”与“海豹胎”药物立法前的阴影[J]. 新知客, 2009(4):99-103. [6] EMA. "Adaptive licensing" or "adaptive pathways":Deregulation under the guise of earlier access[EB/OL].(2015-10-16)[2018-09-13].https://ec.europa.eu/health/sites/health/files/files/committee/stamp/2015-10_stamp3/3c_prescrire_position_paper.pdf. [7] EMA. History of EMA [EB/OL].(2015-01-26)[2018-09-13]. http:// www.ema.europa.eu/docs/en_GB/document_library/Other/2015/01/ WC500180533.pdf. [8] Europe Commission. Directive2001/83/EC of the European Parliament and of the Council [EB/OL].(2001-11-28)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/uri=CELEX:32001L0083&qid=1536934665173&from=EN. [9] Europe Commission. Regulation (EC) No 726/2004 of the European Parliament and of the Council[EB/OL].(2004-03-31)[2018-09-13].https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536935152464&uri=CELEX:32004R0726. [10] Europe Commission. Directive2004/27/EC of the European Parliament and of the Council[EB/OL].(2004-03-31)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536935-784753&uri=CELEX:32004L0027. [11] Europe Commission. Strengthening pharmacovigilance to reduce adverse effects of medicines[EB/OL].(2008-11-10)[2018-09-13]. http://europa.eu/rapid/press-release_MEMO-08-782_en.htm. [12] Assessment of the Community System of Pharmacovigilance- European Commission Public Consultation-presentation of results[EB/OL].(2007-02)[2018-09-13]. https://ec.europa.eu/health/sites/health/files/files/pharmacovigilance/docs/2007_02_26/analysis_consultation_responses_en.pdf. [13] Directive Borg J J, Aislaitner G, Pirozynski M, et al. Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?[J]. Drug Saf, 2011, 34(3):187-197. [14] EMA. Pharmacovigilance Risk Assessment Committee[EB/OL].(2013-03-03)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/03/WC500139609.pdf. [15] Europe Commission. Regulation (EU) No1027/2012 of the European Parliament and of the Council[EB/OL].(2012-10-25)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536940343557&uri=CELEX:32012R1027. [16] Europe Commission. Directive2012/26/EU of the European Parliament and of the Council[EB/OL].(2012-10-25)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=15369404-36186&uri=CELEX:32012L0026. [17] EMA. Guidelines on good pharmacovigilance practices[EB/OL].(2017-10-12)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/10/WC500236404.pdf. [18] EMA. First Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2013-03-21)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/07/WC500146607.pdf. [19] Europe Commission. Directive2010/84/EU of the European Parliament and of the Council [EB/OL].(2010-12-31)[2018-09-13]. https://eur-lex.europa.eu/eli/dir/2010/84/oj. [20] Europe Commission. Regulation (EU) No1235/2010 of the European Parliament and of the Council[EB/OL].(2010-12-31)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=15396-73802636&uri=CELEX:32010R1235. [21] EMA. Guideline on good pharmacovigilance practices (GVP) Module I - Pharmacovigilance systems and their quality systems [EB/OL].(2012-06-22)[2018-09-13]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf. [22] EMA. Guideline on good pharmacovigilance practices (GVP) Module V-Risk management systems [EB/OL].(2012-07-02)[2018-09-13]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf. [23] EMA. Guideline on good pharmacovigilance practices (GVP) Module VI-Collection, management and submission of reports of suspected adverse reactions to medicinal products [EB/OL].(2012-07-02)[2018-09-13]https://www.ema.europa.eu/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. [24] EMA. Guideline on good pharmacovigilance practices (GVP) Module VI Addendum I - Duplicate management of suspected adverse reaction reports [EB/OL].(2012-07-28)[2018-09-20]https://www.ema.europa.eu/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-addendum-i-duplicate-management-suspected_en.pdf. [25] EMA. Guideline on good pharmacovigilance practices (GVP) Module VII - Periodic safety update report (Rev 1) [EB/OL].(2013-12-09)[2018-09-20]https://www.ema.europa.eu/documents/scientific- guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf. [26] EMA. Guideline on good pharmacovigilance practices (GVP) Module IX-Signal management (Rev 1) [EB/OL].(2017-10-09)[2018-09-20]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. [27] EMA. Guideline on good pharmacovigilance practices (GVP) Module X - Additional monitoring[EB/OL].(2013-04-19)[2018-09-20]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf. [28] EMA. List of medicinal products under additional monitoring[EB/OL].(2018-07-25)[2018-09-20]https://www.ema.europa.eu/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en-0.pdf. [29] OU and WP4 Risk Working Group. D4.2 Report on Appraisal of Vaccine Safety Methods [EB/OL].(2014-10-24)[2018-10-06] http://www.advance-vaccines.eu/app/archivos/publicacion/67/ADVAN-CE_D4%202_appraisal%20safety%20methods_final_PU.pdf. [30] EMA. Model for ENCePP[EB/OL].(2007-05-30)[2018-10-06] http://www.encepp.eu/publications/documents/ENCePPConceptPaper_May07.pdf. [31] EMA. Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases[EB/OL].(2013-12-09)[2018-10-06]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-i-vaccines_en.pdf. [32] EMA. First Annual Report on EudraVigilance for the European Parliament, the Council and the Commission [EB/OL].(2013-03-21)[2018-10-06] https://www.ema.europa.eu/documents/report/first-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. [33] EMA.2013 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission [EB/OL].(2014-04-04)[2018-10-06] https://www.ema.europa.eu/documents/report/2013-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. [34] EMA.2014 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2015-02-27)[2018-10-06] https://www.ema.europa.eu/documents/report/2014-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. [35] EMA.2015 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2016-03-17)[2018-10-06] https://www.ema.europa.eu/documents/report/2015-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. [36] EMA.2016 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2017-03-16)[2018-10-06] https://www.ema.europa.eu/documents/report/2016-annual-report-eudravigilance-european-parliament-council-commission_en.pdf. [37] EMA.2017 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2018-03-15)[2018-10-06] https://www.ema.europa.eu/documents/report/2017-annual-report-eudravigilance-european-parliament-council-commission-reporting-period-1-january_en.pdf. [38] 张桂菊, 张桂菊, 初晓艺, 等. 欧盟药物警戒体系对我国的启示[J]. 中国药物警戒, 2015, 12(10):593-596. [39] 董铎, 吴桂枝, 程刚. 欧盟新法规下的药物警戒制度简介[J]. 中国药物警戒, 2012, 9(11):662-665. [40] EMA. EudraVigilance Operational Plan Milestones2018 to 2020 [EB/OL].(2018-06-08)[2018-10-06].https://www.ema.europa.eu/documents/other/eudravigilance-operational-plan-milestones-2018-2020_en.pdf. [41] 武楠, 杨悦. 欧盟药物警戒数据库建设对我国的启示[J]. 中国药物警戒, 2018,15(4)230-233. |
[1] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[2] | GAO Xu, PENG Jin’e, LI Xingwang, ZHANG Wei. Recent research of antiviral drugs and vaccines for Mpox [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 111-116. |
[3] | FU Mengjun, YAO Huihui, ZHU Kexu, WANG Xinyuan, YAO Shangchen. Evaluation of dissolution curves of indapamide tablets between generics and reference formulation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 763-768. |
[4] | LIU Bo, GUO Yunxiao, ZHANG Tong, HUANG Lu, HE Lanying, FAN Huihong. A national reference standard for fructosazine and deoxyfructosazine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 282-285. |
[5] | ZI Wenrui, YANG Qiuyue, SU Jun, XIE Jiang'an. The research development of inoculation safety associated with licensed HPV vaccines in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 311-316. |
[6] | GUAN Haoyue, LIU Nian, QI Mengjie, SUN Baihao, LIU Xuejing, HU Yang, NIU Jianzhao. Quality analysis of donepezil hydrochloride tablet [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1375-1381. |
[7] | TAN Liyuan, CAI Tong, WANG Yan. Research progress in quantitative analysis methods for chemical reference substances [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1209-1216. |
[8] | ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui. One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305. |
[9] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[10] | YANG Qiuyue, SU Jun, ZHANG Xue, XIE Jiangan. Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1141-1147. |
[11] | ZHOU Pengbo, ZHOU Xiaobing, HUANG Ying, GENG Xingchao. Research progress in oncolytic drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 7-11. |
[12] | SUN Yixin, LIU Zhike, ZHAN Siyan. Scoping review of near real-time surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67. |
[13] | FENG Jingnan, ZHAO Houyu, LIU Zhike, ZHAN Siyan. Self-controlled tree temporal scan statistic in active surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 68-73. |
[14] | LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78. |
[15] | LIU Yantao, ZHANG Lingli, LIN Yunzhu, CHEN Li, WANG Li. Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 96-100. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||